title: Pharmacological and haematological results of rat skin burn injury treatment with Cu(II)2(3,5-diisopropylsalicylate)4.
abstract: This research was performed to determine whether or not treatment of burn-injured rats with Cu(II)2(3,5-diisopropylsalicylate)4(Cu(II)2(3,5-DIPS)4) facilitated recovery from burn-injury. Four groups of adult male rats received a standard skin burn 1 h before an initial subcutaneous treatment which was continued daily for three days with either 0, 5, 10 or 20micromol Cu(II)2(3,5-DIPS)4/kg body mass. A fifth group was given no treatment. A sixth group served as a non-burn-injured non-treated normal control group. At 3 h and on days 1, 2, 3, 7 and 14 post-burn-injury blood samples were obtained from rats in all groups for the determination of leukocyte, platelet and erythrocyte counts, clotting times, hemoglobin and hematocrit values. Total protein and middle mass peptides in plasma, as well as plasma lipid and erythrocyte membrane peroxidation products were determined on days 7 and 14. Burn wound healing and body mass were determined daily from day 0 to 6 with a notation of crust rejection by day 14. Treatment with Cu(II)2(3,5-DIPS)4 produced effects consistent with a facilitation of Cu-dependent immune-mediated physiological inflammatory responses to burn injury. It is concluded that treatment of burn injury with Cu(II)2(3,5-DIPS)4 supports Cu-dependent physiological responses involved in overcoming burn injury, which may have been further optimized by continued treatment beyond day 2, the last day of treatment.
authors.affiliation: Sector of Radiation Medicine and Burns, Center of Traumatology, Orthopedics, Burns and Radiology, Ministry of Health, Republic of Armenia, P.O. Box 25, Davidashen, Yerevan, Armenia 375108.
authors.forename: Margarita H
authors.initials: MH
authors.lastname: Malakyan
authors.forename: Sergey A
authors.initials: SA
authors.lastname: Bajinyan
authors.forename: Armenuhi K
authors.initials: AK
authors.lastname: Abrahamyan
authors.forename: Zhasmena H
authors.initials: ZH
authors.lastname: Petrosyan
authors.forename: Nektar K
authors.initials: NK
authors.lastname: Harutyunyan
authors.forename: Vardush A
authors.initials: VA
authors.lastname: Badiryan
authors.forename: John R J
authors.initials: JR
authors.lastname: Sorenson
mesh_terms: D000818:Animals; D001798:Blood Proteins / Q000032:analysis; D002056:Burns / Q000097:blood / Q000188:drug therapy*; D004906:Erythrocyte Count; D004910:Erythrocyte Membrane / Q000378:metabolism; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D007958:Leukocyte Count; D015227:Lipid Peroxidation; D008297:Male; D010976:Platelet Count; D051381:Rats; D011919:Rats, Inbred Strains; D012459:Salicylates / Q000494:pharmacology / Q000627:therapeutic use*; D014914:Whole Blood Coagulation Time
chemical_list: D001798:Blood Proteins; D006454:Hemoglobins; D012459:Salicylates; C030865:copper bis(3,5-diisopropylsalicylate)